Keros Therapeutics (KROS)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Keros Therapeutics (KROS)
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Key Insights
Critical company metrics and information
Share Price
$67.31Market Cap
$2.73 BillionTotal Outstanding Shares
40.51 Million SharesTotal Employees
160Dividend
No dividendIPO Date
April 8, 2020SIC Description
Pharmaceutical PreparationsHomepage
https://www.kerostx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-386,000.00 |
Net Cash Flow From Operating Activities | $-30.50 Million |
Net Cash Flow, Continuing | $125.06 Million |
Net Cash Flow | $125.06 Million |
Net Cash Flow From Financing Activities, Continuing | $155.94 Million |
Net Cash Flow From Investing Activities | $-386,000.00 |
Net Cash Flow From Operating Activities, Continuing | $-30.50 Million |
Net Cash Flow From Financing Activities | $155.94 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Income/Loss From Continuing Operations Before Tax | $388,000.00 |
Diluted Average Shares | $37.59 Million |
Net Income/Loss Attributable To Parent | $-52.96 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-52.96 Million |
Diluted Earnings Per Share | $-1.41 |
Operating Expenses | $59.05 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income/Loss From Continuing Operations After Tax | $-52.96 Million |
Other Operating Expenses | $9.82 Million |
Net Income/Loss | $-52.96 Million |
Basic Earnings Per Share | $-1.41 |
Benefits Costs and Expenses | $0.00 |
Revenues | $388,000.00 |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Costs And Expenses | $59.05 Million |
Basic Average Shares | $37.59 Million |
Nonoperating Income/Loss | $5.70 Million |
Research and Development | $49.23 Million |
Operating Income/Loss | $-58.66 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Other Current Liabilities | $16.00 Million |
Equity | $532.84 Million |
Fixed Assets | $4.37 Million |
Current Assets | $552.05 Million |
Wages | $8.03 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $532.84 Million |
Assets | $579.27 Million |
Accounts Payable | $4.98 Million |
Liabilities | $46.44 Million |
Liabilities And Equity | $579.27 Million |
Noncurrent Assets | $27.23 Million |
Current Liabilities | $29.01 Million |
Noncurrent Liabilities | $17.43 Million |
Other Non-current Assets | $22.86 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.